

# **Global GLP-1 Receptor Agonist Market Size study, by Product (Ozempic, Zepbound), by Application (Diabetes, Obesity), by Route of Administration (Parenteral, Oral), and Regional Forecasts 2022–2032**

<https://marketpublishers.com/r/G87DBF2863B1EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G87DBF2863B1EN

## **Abstracts**

Global GLP-1 Receptor Agonist Market is valued at approximately USD 45.51 billion in 2023 and is anticipated to grow with a robust CAGR of 17.46% over the forecast period from 2024 to 2032. Glucagon-like peptide-1 (GLP-1) receptor agonists have quickly emerged as game-changers in the treatment of chronic metabolic disorders, specifically type 2 diabetes and obesity. These agents mimic the action of native GLP-1, a hormone that enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and induces satiety. As the global burden of obesity and diabetes reaches alarming proportions, these therapeutics have found growing favor among healthcare providers and patients alike for their dual benefits in glycemic control and weight reduction. The paradigm shift away from conventional therapies toward GLP-1-based regimens reflects an evolving healthcare consensus around holistic metabolic care.

The commercial success of blockbuster drugs like Ozempic and the rapid market uptake of newer entrants such as Zepbound are underpinned by a convergence of factors—rising disease prevalence, expanding payer coverage, and growing patient acceptance of long-term injectable and oral therapies. Moreover, the increased prioritization of cardiometabolic outcomes in treatment algorithms has significantly boosted the strategic positioning of GLP-1 receptor agonists in therapeutic protocols. Simultaneously, global pharmaceutical giants are doubling down on R&D investments to expand GLP-1 utility beyond diabetes into obesity, nonalcoholic steatohepatitis (NASH), and cardiovascular risk management, unlocking untapped market potential.

Despite soaring demand, the market faces its share of headwinds. High cost of

treatment, concerns over long-term safety, and limited access in low- and middle-income countries temper growth in certain regions. Additionally, supply chain bottlenecks and production constraints have occasionally led to product shortages, highlighting the need for robust manufacturing infrastructure. Nevertheless, ongoing innovations in oral delivery platforms, patient-centric dosing devices, and combination therapies are expected to mitigate these barriers and enhance long-term adoption across diverse healthcare settings.

Regionally, North America commands the largest share of the GLP-1 receptor agonist market, driven by an entrenched base of chronic disease patients, favorable reimbursement frameworks, and early adoption of next-gen therapies. Europe follows suit with countries such as Germany and the UK showing strong prescription growth, aided by progressive treatment guidelines and policy support. Meanwhile, Asia Pacific is set to become the fastest-growing regional market, propelled by the diabetic and obese population explosion in China and India, expanding urban healthcare networks, and improving affordability through generic manufacturing. Latin America and the Middle East & Africa, though at nascent stages, are increasingly integrating GLP-1 therapies into national formularies, thanks to global partnerships and healthcare modernization efforts.

Major market player included in this report are:

Novo Nordisk A/S

Eli Lilly and Company

Pfizer Inc.

Sanofi S.A.

Boehringer Ingelheim International GmbH

AstraZeneca PLC

Zealand Pharma A/S

GlaxoSmithKline PLC

Hanmi Pharmaceutical Co., Ltd.

Amgen Inc.

Roche Holding AG

Merck & Co., Inc.

Bayer AG

Teva Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Company Limited

The detailed segments and sub-segment of the market are explained below:

#### By Product

Ozempic

Zepbound

#### By Application

Diabetes

Obesity

#### By Route of Administration

Parenteral

Oral

#### By Region:

## North America

U.S.

Canada

## Europe

UK

Germany

France

Spain

Italy

Rest of Europe

## Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

## Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical Year – 2022

Base Year – 2023

Forecast Period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032

Annualized revenues and regional level analysis for each market segment

Detailed analysis of geographical landscape with country-level analysis of major regions

Competitive landscape with information on major players in the market

Analysis of key business strategies and recommendations on future market approach

Analysis of competitive structure of the market

Demand side and supply side analysis of the market

## Contents

### **CHAPTER 1. GLOBAL GLP-1 RECEPTOR AGONIST MARKET EXECUTIVE SUMMARY**

- 1.1. Global GLP-1 Receptor Agonist Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By Product
  - 1.3.2. By Application
  - 1.3.3. By Route of Administration
- 1.4. Key Trends
- 1.5. Reimbursement & Access Impact
- 1.6. Analyst Recommendation & Conclusion

### **CHAPTER 2. GLOBAL GLP-1 RECEPTOR AGONIST MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply Side Analysis
    - 2.3.3.1. Manufacturing Capacity
    - 2.3.3.2. Regulatory Environment
    - 2.3.3.3. Pricing & Reimbursement
    - 2.3.3.4. Competitive Landscape
  - 2.3.4. Demand Side Analysis
    - 2.3.4.1. Disease Prevalence Trends
    - 2.3.4.2. Treatment Guidelines
    - 2.3.4.3. Patient Awareness & Adoption
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

### **CHAPTER 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET DYNAMICS**

- 3.1. Market Drivers

- 3.1.1. Escalating Prevalence of Diabetes and Obesity
- 3.1.2. Emphasis on Cardiometabolic Outcomes
- 3.1.3. Increased R&D Investments and Pipeline Expansion
- 3.2. Market Challenges
  - 3.2.1. High Treatment Costs and Reimbursement Barriers
  - 3.2.2. Long-term Safety Concerns and Access Limitations in Emerging Markets
- 3.3. Market Opportunities
  - 3.3.1. Innovations in Oral Delivery and Patient-Centric Devices
  - 3.3.2. Combination Therapies and Indication Expansion (NASH, CV Risk)
  - 3.3.3. Generic and Biosimilar Entrants in Developing Economies

## **CHAPTER 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET INDUSTRY ANALYSIS**

- 4.1. Porter's 5 Force Model
  - 4.1.1. Bargaining Power of Suppliers
  - 4.1.2. Bargaining Power of Buyers
  - 4.1.3. Threat of New Entrants
  - 4.1.4. Threat of Substitutes
  - 4.1.5. Competitive Rivalry
- 4.2. PESTEL Analysis
  - 4.2.1. Political
  - 4.2.2. Economic
  - 4.2.3. Social
  - 4.2.4. Technological
  - 4.2.5. Environmental
  - 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion

## **CHAPTER 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE & FORECASTS BY PRODUCT 2022–2032**

- 5.1. Segment Dashboard
- 5.2. Global Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  - 5.2.1. Ozempic



### 5.2.2. Zepbound

## **CHAPTER 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE & FORECASTS BY APPLICATION 2022–2032**

### 6.1. Segment Dashboard

### 6.2. Global Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)

#### 6.2.1. Diabetes

#### 6.2.2. Obesity

## **CHAPTER 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022–2032**

### 7.1. Segment Dashboard

### 7.2. Global Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)

#### 7.2.1. Parenteral

#### 7.2.2. Oral

## **CHAPTER 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE & FORECASTS BY REGION 2022–2032**

### 8.1. North America Market

#### 8.1.1. U.S. Market

#### 8.1.2. Canada Market

### 8.2. Europe Market

#### 8.2.1. U.K. Market

#### 8.2.2. Germany Market

#### 8.2.3. France Market

#### 8.2.4. Spain Market

#### 8.2.5. Italy Market

#### 8.2.6. Rest of Europe Market

### 8.3. Asia Pacific Market

#### 8.3.1. China Market

#### 8.3.2. India Market

#### 8.3.3. Japan Market

#### 8.3.4. Australia Market

#### 8.3.5. South Korea Market

#### 8.3.6. Rest of Asia Pacific Market

#### 8.4. Latin America Market

##### 8.4.1. Brazil Market

##### 8.4.2. Mexico Market

##### 8.4.3. Rest of Latin America Market

#### 8.5. Middle East & Africa Market

##### 8.5.1. Saudi Arabia Market

##### 8.5.2. South Africa Market

##### 8.5.3. Rest of Middle East & Africa Market

### **CHAPTER 9. COMPETITIVE INTELLIGENCE**

#### 9.1. Key Company SWOT Analysis

##### 9.1.1. Novo Nordisk A/S

##### 9.1.2. Eli Lilly and Company

##### 9.1.3. Pfizer Inc.

#### 9.2. Top Market Strategies

#### 9.3. Company Profiles

##### 9.3.1. Novo Nordisk A/S

###### 9.3.1.1. Key Information

###### 9.3.1.2. Overview

###### 9.3.1.3. Financial (Subject to Data Availability)

###### 9.3.1.4. Product Summary

###### 9.3.1.5. Market Strategies

##### 9.3.2. Eli Lilly and Company

##### 9.3.3. Pfizer Inc.

##### 9.3.4. Sanofi S.A.

##### 9.3.5. Boehringer Ingelheim International GmbH

##### 9.3.6. AstraZeneca PLC

##### 9.3.7. Zealand Pharma A/S

##### 9.3.8. GlaxoSmithKline PLC

##### 9.3.9. Hanmi Pharmaceutical Co., Ltd.

##### 9.3.10. Amgen Inc.

### **CHAPTER 10. RESEARCH PROCESS**

#### 10.1. Research Process

##### 10.1.1. Data Mining

##### 10.1.2. Analysis

##### 10.1.3. Market Estimation

10.1.4. Validation

10.1.5. Publishing

10.2. Research Attributes

## I would like to order

Product name: Global GLP-1 Receptor Agonist Market Size study, by Product (Ozempic, Zepbound), by Application (Diabetes, Obesity), by Route of Administration (Parenteral, Oral), and Regional Forecasts 2022–2032

Product link: <https://marketpublishers.com/r/G87DBF2863B1EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G87DBF2863B1EN.html>